Comparative Pharmacology
Head-to-head clinical analysis: CORDRAN SP versus HC 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORDRAN SP versus HC 4.
CORDRAN SP vs HC #4
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins), inhibiting arachidonic acid release and subsequent prostaglandin and leukotriene synthesis, thereby mediating anti-inflammatory, antipruritic, and vasoconstrictive effects.
HC #4 is a complex homeopathic preparation with no well-defined molecular mechanism; it is believed to act via hormesis or placebo effects.
Apply a thin film to the affected area 1 to 2 times daily. Use the smallest amount for adequate therapy. Do not use for more than 2 weeks per course of treatment.
Hydrocortisone 100-300 mg IV bolus, followed by 100-200 mg IV every 6 hours for 24-48 hours; then taper as clinically indicated.
None Documented
None Documented
Terminal half-life approximately 48 hours; prolonged with hepatic impairment.
Terminal elimination half-life: 12 hours (range 10–14 hours). Extends to 24 hours in severe renal impairment (CrCl <30 mL/min); dose adjustment recommended.
Primarily renal as inactive metabolites; <5% unchanged. Minimal biliary/fecal elimination.
Renal excretion of unchanged drug: 95%; fecal/biliary: <5%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid